Celldex Therapeutics, Inc. (CLDX)

$38.53

-1.1

(-2.78%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Celldex Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 268.0K → 4.13M (in $), with an average increase of 72.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -22.41M → -43.30M (in $), with an average decrease of 24.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 31.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 176.8%

Performance

  • $38.39
    $39.94
    $38.53
    downward going graph

    0.36%

    Downside

    Day's Volatility :3.88%

    Upside

    3.53%

    downward going graph
  • $22.11
    $53.18
    $38.53
    downward going graph

    42.62%

    Downside

    52 Weeks Volatility :58.42%

    Upside

    27.55%

    downward going graph

Returns

PeriodCelldex Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-0.08%
-0.7%
0.0%
6 Months
65.13%
6.6%
0.0%
1 Year
15.3%
3.7%
-1.5%
3 Years
64.1%
14.0%
-21.8%

Highlights

Market Capitalization
2.6B
Book Value
$7.68
Earnings Per Share (EPS)
-2.92
PEG Ratio
0.0
Wall Street Target Price
70.71
Profit Margin
0.0%
Operating Margin TTM
-850.33%
Return On Assets TTM
-21.7%
Return On Equity TTM
-37.45%
Revenue TTM
6.9M
Revenue Per Share TTM
0.14
Quarterly Revenue Growth YOY
156.1%
Gross Profit TTM
-79.9M
EBITDA
-139.0M
Diluted Eps TTM
-2.92
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.01
EPS Estimate Next Year
-3.09
EPS Estimate Current Quarter
-0.74
EPS Estimate Next Quarter
-0.74

Analyst Recommendation

Buy
    84%Buy
    7%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Celldex Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
1
1
00

Analyst Forecast

What analysts predicted

Upside of 83.52%

Current $38.53
Target $70.71

Company Financials

FY18Y/Y Change
Revenue
9.5M
↓ 25.15%
Net Income
-151.2M
↑ 62.51%
Net Profit Margin
-1.6K%
↓ 855.01%
FY19Y/Y Change
Revenue
3.6M
↓ 62.54%
Net Income
-50.4M
↓ 66.68%
Net Profit Margin
-1.4K%
↑ 175.27%
FY20Y/Y Change
Revenue
7.4M
↑ 107.61%
Net Income
-59.8M
↑ 18.68%
Net Profit Margin
-805.88%
↑ 603.92%
FY21Y/Y Change
Revenue
4.7M
↓ 37.3%
Net Income
-70.5M
↑ 17.95%
Net Profit Margin
-1.5K%
↓ 710.16%
FY22Y/Y Change
Revenue
2.4M
↓ 49.32%
Net Income
-122.8M
↑ 74.13%
Net Profit Margin
-5.2K%
↓ 3693.25%
FY23Y/Y Change
Revenue
6.9M
↑ 192.02%
Net Income
-141.4M
↑ 15.19%
Net Profit Margin
-2.1K%
↑ 3154.53%
Q3 FY22Q/Q Change
Revenue
407.0K
↑ 149.69%
Net Income
-25.0M
↓ 52.52%
Net Profit Margin
-6.1K%
↑ 26117.63%
Q4 FY22Q/Q Change
Revenue
1.6M
↑ 296.31%
Net Income
-23.7M
↓ 5.08%
Net Profit Margin
-1.5K%
↑ 4663.93%
Q1 FY23Q/Q Change
Revenue
967.0K
↓ 40.05%
Net Income
-22.4M
↓ 5.39%
Net Profit Margin
-2.3K%
↓ 849.24%
Q2 FY23Q/Q Change
Revenue
268.0K
↓ 72.29%
Net Income
-30.5M
↑ 36.08%
Net Profit Margin
-11.4K%
↓ 9063.35%
Q3 FY23Q/Q Change
Revenue
1.5M
↑ 466.04%
Net Income
-38.3M
↑ 25.43%
Net Profit Margin
-2.5K%
↑ 8859.26%
Q4 FY23Q/Q Change
Revenue
4.1M
↑ 172.31%
Net Income
-43.3M
↑ 13.19%
Net Profit Margin
-1.0K%
↑ 1473.76%
FY18Y/Y Change
Total Assets
155.8M
↓ 50.63%
Total Liabilities
31.7M
↓ 59.94%
FY19Y/Y Change
Total Assets
122.9M
↓ 21.1%
Total Liabilities
28.9M
↓ 8.95%
FY20Y/Y Change
Total Assets
235.8M
↑ 91.84%
Total Liabilities
26.5M
↓ 8.39%
FY21Y/Y Change
Total Assets
444.7M
↑ 88.54%
Total Liabilities
25.2M
↓ 4.92%
FY22Y/Y Change
Total Assets
352.7M
↓ 20.67%
Total Liabilities
26.5M
↑ 5.37%
FY23Y/Y Change
Total Assets
465.6M
↑ 32.0%
Total Liabilities
36.5M
↑ 37.41%
Q3 FY22Q/Q Change
Total Assets
369.2M
↓ 8.37%
Total Liabilities
23.8M
↓ 37.12%
Q4 FY22Q/Q Change
Total Assets
352.7M
↓ 4.47%
Total Liabilities
26.5M
↑ 11.43%
Q1 FY23Q/Q Change
Total Assets
324.5M
↓ 8.0%
Total Liabilities
21.8M
↓ 17.91%
Q2 FY23Q/Q Change
Total Assets
299.3M
↓ 7.77%
Total Liabilities
21.8M
↓ 0.02%
Q3 FY23Q/Q Change
Total Assets
280.3M
↓ 6.37%
Total Liabilities
33.5M
↑ 54.03%
Q4 FY23Q/Q Change
Total Assets
465.6M
↑ 66.14%
Total Liabilities
36.5M
↑ 8.7%
FY18Y/Y Change
Operating Cash Flow
-75.2M
↓ 24.71%
Investing Cash Flow
29.8M
↓ 35.84%
Financing Cash Flow
29.4M
↓ 42.6%
FY19Y/Y Change
Operating Cash Flow
-46.4M
↓ 38.31%
Investing Cash Flow
17.1M
↓ 42.72%
Financing Cash Flow
16.3M
↓ 44.78%
FY20Y/Y Change
Operating Cash Flow
-40.4M
↓ 12.95%
Investing Cash Flow
-98.2M
↓ 675.05%
Financing Cash Flow
171.2M
↑ 953.24%
FY21Y/Y Change
Operating Cash Flow
-60.9M
↑ 50.75%
Investing Cash Flow
-216.2M
↑ 120.08%
Financing Cash Flow
272.4M
↑ 59.07%
FY22Y/Y Change
Operating Cash Flow
-103.7M
↑ 70.31%
Investing Cash Flow
89.9M
↓ 141.61%
Financing Cash Flow
4.1M
↓ 98.5%
Q3 FY22Q/Q Change
Operating Cash Flow
-35.2M
↑ 58.21%
Investing Cash Flow
23.1M
↓ 8.75%
Financing Cash Flow
2.3M
↑ 3147.89%
Q4 FY22Q/Q Change
Operating Cash Flow
-21.8M
↓ 38.16%
Investing Cash Flow
31.2M
↑ 35.31%
Financing Cash Flow
1.4M
↓ 39.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-28.6M
↑ 31.28%
Investing Cash Flow
52.6M
↑ 68.42%
Financing Cash Flow
694.0K
↓ 50.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-27.2M
↓ 4.81%
Investing Cash Flow
1.2M
↓ 97.79%
Financing Cash Flow
133.0K
↓ 80.84%

Technicals Summary

Sell

Neutral

Buy

Celldex Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
-3.25%
65.13%
15.3%
64.1%
945.65%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
NA
NA
0.0
-3.01
-0.37
-0.22
NA
7.68
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
Buy
$2.6B
945.65%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • FMR Inc

    10.73%

  • Wellington Management Company LLP

    9.86%

  • BlackRock Inc

    5.59%

  • Eventide Asset Management, LLC

    5.53%

  • RTW INVESTMENTS, LLC

    5.27%

  • Polar Capital Holdings PLC

    4.77%

Corporate Announcements

  • Celldex Therapeutics, Inc. Earnings

    Celldex Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Organization
Celldex Therapeutics, Inc.
Employees
160
CEO
Mr. Anthony S. Marucci M.B.A.
Industry
Health Technology

Discover More

FAQs